Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has shared an update.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has released its audited annual results for the year ended 31 December 2025, which have been reviewed by the board’s audit committee. The company stated that the annual results announcement includes the full text of its 2025 H-share annual report, prepared in line with Hong Kong listing rules on preliminary annual results disclosures.
The 2025 annual report is scheduled to be published on the Hong Kong Exchanges and Clearing website and the company’s own site by the end of April 2026. The announcement also confirms the current composition of the board, highlighting continuity in leadership under chairman and chief executive officer Shen Yuelei, which signals governance stability for investors and other stakeholders.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong under stock code 2315. The group focuses on pharmaceutical research and development and operates through multiple subsidiaries, targeting both domestic and international capital markets via its H-share listing.
Average Trading Volume: 1,913,740
Technical Sentiment Signal: Hold
Current Market Cap: HK$22.61B
Find detailed analytics on 2315 stock on TipRanks’ Stock Analysis page.